A dual-amplified ROS-responsive nanosystem with self-accelerating drug release for synergistic chemotherapy

Jun Li; Qingyu Zong; Zhongyi Zhao; Youyong Yuan

doi:10.1039/d3cc00052d

A dual-amplified ROS-responsive nanosystem with self-accelerating drug release for synergistic chemotherapy

Chem Commun (Camb). 2023 Mar 9;59(21):3142-3145. doi: 10.1039/d3cc00052d.

Authors

Jun Li¹, Qingyu Zong², Zhongyi Zhao³, Youyong Yuan^{2

4

5}

Affiliations

¹ School of Biology and Biological Engineering, South China University of Technology, Guangzhou, 510006, P. R. China. yuanyy@scut.edu.cn.
² National Engineering Research Center for Tissue Restoration and Reconstruction, South China University of Technology, Guangzhou, 510006, P. R. China.
³ Key Laboratory of Biomedical Materials and Engineering of the Ministry of Education, South China University of Technology, Guangzhou, 510006, P. R. China.
⁴ School of Biomedical Sciences and Engineering, Guangzhou International Campus, South China University of Technology, Guangzhou, 511442, P. R. China.
⁵ Guangdong Provincial Key Laboratory of Biomedical Engineering, South China University of Technology, Guangzhou, 510006, P. R. China.

PMID: 36811610
DOI: 10.1039/d3cc00052d

Abstract

In this work, we have developed a tumor-specific self-accelerating prodrug activation nanosystem consisting of self-amplifying degradable polyprodrug PEG-TA-CA-DOX and encapsulated fluorescent prodrug BCyNH₂, equipped with a reactive oxygen species dual-cycle amplification effect. Furthermore, activated CyNH₂ is a therapeutic agent with potential to synergistically improve chemotherapy.

MeSH terms

Cell Line, Tumor
Doxorubicin / pharmacology
Drug Delivery Systems
Drug Liberation
Nanoparticles*
Prodrugs* / pharmacology
Reactive Oxygen Species

Substances

Prodrugs
Reactive Oxygen Species
Doxorubicin